RNS Number : 8132S
Aptamer Group PLC
08 November 2023

8 November 2023

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Notice of Results and Investor Presentation

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, will announce its full year results for the year ended 30 June 2023 on Thursday 9 November 2023.

The Company is pleased to announce that Dr Arron Tolley (Chief Technical Officer), Dr David Bunka (Chief Scientific Officer), and Andrew Rapson (Chief Financial Officer) will provide a live presentation relating to the Final Results via Investor Meet Company on Thursday 9 November 2023 at 3:00pm GMT.

The presentation is open to all existing and potential shareholders. Questions can be submitted at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Aptamer Group, via: https://www.investormeetcompany.com/aptamer-group-plc/register-investor

Investors who already follow Aptamer Group on the Investor Meet Company platform will automatically be invited.

- ENDS -

For further information, please contact:

Aptamer Group plc

Steve Hull

+44 (0) 1904 217 404

SPARK Advisory Partners Limited - Nominated Adviser

Andrew Emmott / Adam Dawes

+44 (0) 20 3368 3550

Turner Pope Investments (TPI) Limited - Broker

James Pope / Andrew Thacker

+44 (0) 20 3657 0050

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer® platform.

Optimer® binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion. Optimer® binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer has successfully delivered projects for global pharma companies, diagnostic development companies and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer® technology and processes, scientists and collaborators can make faster, more informed decisions that support discovery and development across the Life Sciences.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORBPBTTMTBMBPJ